Imaging Brain Changes Linked to Depression in Parkinson's Disease
Tests ketamine and a brain scan in adults with Parkinson's disease and depression.
Plain-language title generated from the registry record
Registry title: Imaging Depression in Parkinson's Disease
Key facts
- Where
- New Haven, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
Source: NCT06402955, who can take part
Where in United States
- Yale UniversityNew Haven, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Yale University
- Trial code
- NCT06402955
- Record updated
- 10 March 2026
- Original description
The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.Read full original descriptionShow less
Identifying the Neural Basis of Depression in Parkinson's Disease
The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.
Inclusion: Age 40-80; For women of reproductive potential, a negative pregnancy test at screening and scanning; For PD patients, clinical diagnosis of PD, able to consent and tolerate PET procedures; For PD depression patients - at least moderate symptom severity as determined by at least 15 on the MADRS, which has shown maximum discrimination between depressed and non-depressed PD patients; For dPD patients undergoing ketamine, abstinence from drugs of abuse, other than alcohol, cannabis, nicotine and caffeine for the duration of the study. Patients with substance use disorders as defined by the DSM-5 will be excluded.
Exclusion: Prior radiation exposure for research purposes within such that participation in this study would place them over FDA limits for annual radiation exposure; Medications affecting SV2A availability (e.g. levetiracetam); For dPD patients receiving ketamine, uncontrolled hypertension, defined as average blood pressure greater than or equal to 140 mmHg or an average diastolic blood pressure greater than or equal to 90 mmHg among those patients who have hypertension; Dementia (Montreal Cognitive Assessment (MoCA) score <21); A significant primary DSM-5 psychiatric disorder except for MDD; A history of or current significant medical (e.g. cardiovascular, renal), or neurological (e.g. cerebrovascular, seizure, traumatic brain injury) illness other than PD that is unstable and significantly increase their risk and/or might affect the study objectives, as determined by study physicians; For patients undergoing arterial sampling for the PET scan: Iodine allergy, bleeding disorder and/or use of blood thinning medication; Contraindications to MRI; Inability to provide written informed consent according to the Yale Human Investigation Committee (HIC) guidelines in English.